Enfermedad pulmonar intersticial asociada a esclerosis sistémica (EPI-ES)
Nintedanib dose adjustments in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD): 2-year data from SENSCIS-ON
Allanore Y et al.
Effects of nintedanib in subjects with limited cutaneous systemic sclerosis (lcSSc) and interstitial lung disease (ILD): data from the SENSCIS trial
Allanore Y et al.
Co-creation of a telemedicine guide for patients with systemic sclerosis
Farrington S et al.
SC-ES-09519